Evogene traded at 122.00 this Thursday October 1st, decreasing 6.10 or 4.76 percent since the previous trading session. Looking back, over the last four weeks, Evogene lost 25.02 percent. Over the last 12 months, its price fell by 69.58 percent. Looking ahead, we forecast Evogene to be priced at 132.20 by the end of this quarter and at 120.36 in one year, according to Trading Economics global macro models projections and analysts expectations.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.